Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology

Clinical trial NCT00950755 · COMPLETED

Trial details

NCT number: NCT00950755
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma, Non-Hodgkin

Start date: 1998-06-01
Primary completion: 2011-04-01
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.